E-drug: Brazil and US ARV prices compared
-------------------------------------------------------------------------
Brazil and US ARV prices compared with affordability analysis
In the US, the GDP per person living with HIV is $11,574,242. In
Brazil, the GDP per person living with HIV is $741,618, or 6.4 percent
of the US income per person living with HIV. One measure of an
affordable price for ARV products in Brazil is the ratio of US to Brazil
GDP/HIV+. If prices are 6.4 percent of the US price, they are
probably affordable if purchased by the State. Prices for ARV
products in Brazil depend upon when the products were invented. All
ARV products invented before 1996 are generics in Brazil. Products
invented after 1996 are on patent. All post 1996 products are much
more expensive. The following is a comparison of US and Brazil
prices for seven important ARV products. The average price of
products invented before 1996 is 6 percent of the US price. The
average price of the products invented after 1996 is 29 percent of the
US price. If Brazil cannot get the new drugs priced much lower, it will
be difficult for Brazil to sustain universal access to HAART treatment.
Jamie
DRUG/ /USA / Brazil / %USA
Prior 1996 inventions off patent in Brazil
AZT/ $3,767 / $ 241 / 6%
3TC/ $3,285 / $ 168 / 5%
Nevirapine/ $3,891 / $ 204 / 5%
ARV Drugs patented in Brazil
Nelfinavir/ $6,931 / $1,741 / 25%
Efavirenz/ $4,782 / $ 767 / 16%
Lopinaivr+Ritonavir / $3,931 / $1,643 / 42%
AZT+3TC (Combivir) / $7,023 / $2,190 / 31%
--
James Love, Director, Consumer Project on Technology
http://www.cptech.org, mailto:james.love@cptech.org
tel. +1.202.387.8030, mobile +1.202.361.3040
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug